Pramlintide
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 636
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo-P + Placebo-M | 4 participants | 0 participants | 5 participants | n/r | n/r |
| Pramlintide 360 mcg + Placebo-M | 31 participants | 6 participants | 5 participants | n/r | n/r |
| Placebo-P + Metreleptin 5.0 mg | 4 participants | 3 participants | 3 participants | n/r | n/r |
| Pramlintide 180 mcg + Metreleptin 2.5 mg | 27 participants | 0 participants | 5 participants | n/r | n/r |
| Pramlintide 180 mcg + Metreleptin 5.0 mg | 21 participants | 2 participants | 4 participants | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 1.25 mg | 26 participants | 5 participants | 4 participants | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 2.5 mg | 29 participants | 1 participants | 7 participants | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 5.0 mg | 19 participants | 1 participants | 3 participants | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.